Medicus Pharma targets Gorlin Syndrome with SkinJect - ICYMI
Yahoo Finance · Aug 1, 2026 · Medicus Pharma Ltd. Warrant (MDCXW)
Medicus Pharma (NASDAQ:MDCX) earlier this week announced that the US Food and Drug Administration (FDA) has cleared the company's Phase 2b registration-enabling clinical trial for SkinJect in patients with Gorlin syndrome, representing an important regulatory milestone for its lead...
Not investment advice. Cached headline, not a full reprint.